» Articles » PMID: 19747353

Morbidity of Open Retroperitoneal Lymph Node Dissection for Testicular Cancer: Contemporary Perioperative Data

Overview
Journal BJU Int
Specialty Urology
Date 2009 Sep 15
PMID 19747353
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To review differences between primary retroperitoneal lymph node dissection (P-RPLND) and RPLND after chemotherapy (PC-RPLND) in a contemporary series of patients with testicular cancer, to validate the proposed low morbidity.

Patients And Methods: Patients who had undergone RPLND at our institution in 2001-2008 were identified and their clinical charts reviewed; in all, 190 were identified and perioperative data obtained.

Results: Of the 190 patients who had RPLND, 98 (52%) and 92 (48%) had P- and PC-RPLND, respectively. Histology of the orchidectomy specimen consisted of embryonal carcinoma in 146 (76%) patients, also including lymphovascular invasion in 83 (44%). The mean (range) operative duration was 206 (110-475) min and the mean blood loss was 294 (50-7000) mL. The median hospital stay was 4 days. Mean blood loss, operative duration and hospital stay were significantly less for the P-RPLND than for PC-RPLND groups (P < 0.05). There were 18 (9%) perioperative complications in all. There were no deaths in either group.

Conclusions: The short-term morbidity of open RPLND is acceptable, and open RPLND is safe and effective at select tertiary centres. When compared with historical data, the present contemporary series shows that the operative duration, blood loss and hospital stay have improved, with few complications. These contemporary data should be considered when comparing laparoscopic with open RPLND.

Citing Articles

Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer at a National Referral Centre.

Evmorfopoulos K, Vlachostergios P, Chasiotis G, Karatzas A, Zachos I, Koukoulis G Cancers (Basel). 2025; 17(4).

PMID: 40002203 PMC: 11853486. DOI: 10.3390/cancers17040608.


Testicular Cancer Treatments and Sexuality: A Narrative Review.

Raffo M, Di Naro A, Napolitano L, Aveta A, Cilio S, Pandolfo S Medicina (Kaunas). 2024; 60(4).

PMID: 38674232 PMC: 11051825. DOI: 10.3390/medicina60040586.


Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer.

McClintock G, Goolam A, Perera D, Downey R, Leslie S, Grimison P Asian J Urol. 2024; 11(1):121-127.

PMID: 38312811 PMC: 10837656. DOI: 10.1016/j.ajur.2022.03.010.


Clinical efficacy and safety of robotic retroperitoneal lymph node dissection for testicular cancer: a systematic review and meta-analysis.

Yuan Y, Zhang D, Ning Y, Luo H, Qiu X, Tan Y Front Oncol. 2024; 13:1257528.

PMID: 38169835 PMC: 10758414. DOI: 10.3389/fonc.2023.1257528.


Unilateral post-chemotherapy robot-assisted retroperitoneal lymph node dissection in Stage II non-seminomatous germ cell tumor: A tertiary care experience.

Franzese D, Tufano A, Izzo A, Muscariello R, Grimaldi G, Quarto G Asian J Urol. 2023; 10(4):440-445.

PMID: 38024429 PMC: 10659970. DOI: 10.1016/j.ajur.2023.05.002.